BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-molina M, Axmann J, Kirchgaessler K, Samara K, Gilberg F, Cottin V. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Respiratory Medicine 2020;8:147-57. [DOI: 10.1016/s2213-2600(19)30341-8] [Cited by in Crossref: 132] [Cited by in F6Publishing: 204] [Article Influence: 66.0] [Reference Citation Analysis]
Number Citing Articles
1 Cottin V, Martinez FJ, Smith V, Walsh SL. Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives. Eur Respir Rev 2022;31:220003. [DOI: 10.1183/16000617.0003-2022] [Reference Citation Analysis]
2 Górska K, Maskey-Warzęchowska M, Barnaś M, Białas A, Barczyk A, Jagielska-Len H, Jassem E, Kania A, Lewandowska K, Majewski S, Martusewicz-Boros MM, Piotrowski WJ, Siemińska A, Sładek K, Sobiecka M, Trzaska-Sobczak M, Tomkowski W, Żołnowska B, Krenke R. Therapeutic decisions in a cohort of patients with idiopathic pulmonary fibrosis: a multicenter, prospective survey from Poland. Ther Adv Chronic Dis 2022;13:20406223221117982. [PMID: 36052286 DOI: 10.1177/20406223221117982] [Reference Citation Analysis]
3 Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. The Lancet 2022;400:769-86. [DOI: 10.1016/s0140-6736(22)01052-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Valenzuela C, Cottin V. Epidemiology and real-life experience in progressive pulmonary fibrosis. Curr Opin Pulm Med 2022;28:407-13. [PMID: 35938201 DOI: 10.1097/MCP.0000000000000908] [Reference Citation Analysis]
5 Al-Kuraishy HM, Batiha GE, Faidah H, Al-Gareeb AI, Saad HM, Simal-Gandara J. Pirfenidone and post-Covid-19 pulmonary fibrosis: invoked again for realistic goals. Inflammopharmacology 2022. [PMID: 36044102 DOI: 10.1007/s10787-022-01027-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Gao L, Xiao C, Cheng T, Wang Z, Xia W, Teekaraman Y. Cellular Imaging Analysis Algorithm-Based Assessment and Prediction of Disease in Patients with Acute Lung Injury. Contrast Media & Molecular Imaging 2022;2022:1-11. [DOI: 10.1155/2022/3193671] [Reference Citation Analysis]
7 Cottin V, Selman M, Inoue Y, Wong AW, Corte TJ, Flaherty KR, Han MK, Jacob J, Johannson KA, Kitaichi M, Lee JS, Agusti A, Antoniou KM, Bianchi P, Caro F, Florenzano M, Galvin L, Iwasawa T, Martinez FJ, Morgan RL, Myers JL, Nicholson AG, Occhipinti M, Poletti V, Salisbury ML, Sin DD, Sverzellati N, Tonia T, Valenzuela C, Ryerson CJ, Wells AU. Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. Am J Respir Crit Care Med 2022;206:e7-e41. [PMID: 35969190 DOI: 10.1164/rccm.202206-1041ST] [Reference Citation Analysis]
8 Sun K, Fisher JH, Pagnoux C. Interstitial Lung Disease in ANCA-Associated Vasculitis: Pathogenic Considerations and Impact for Patients' Outcomes. Curr Rheumatol Rep 2022;24:259-67. [PMID: 35794350 DOI: 10.1007/s11926-022-01078-2] [Reference Citation Analysis]
9 Mullin ML, Churg A, Ryerson CJ. Management of fibrotic hypersensitivity pneumonitis. Curr Opin Pulm Med 2022. [PMID: 35861479 DOI: 10.1097/MCP.0000000000000904] [Reference Citation Analysis]
10 Zhou Y, Fang C, Sun Q, Dong Y. Relevance of RNA N6-Methyladenosine Regulators for Pulmonary Fibrosis: Implications for Chronic Hypersensitivity Pneumonitis and Idiopathic Pulmonary Fibrosis. Front Genet 2022;13:939175. [DOI: 10.3389/fgene.2022.939175] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Bowman WS, Dempsey T. Works in Progress: Using Administrative Data to Estimate the Prevalence of Progressive Fibrosing Interstitial Lung Disease. Ann Am Thorac Soc 2022;19:1095-7. [PMID: 35772099 DOI: 10.1513/AnnalsATS.202203-276ED] [Reference Citation Analysis]
12 Meng K, Tian M, Gui X, Xie M, Gao Y, Shi S, Zhao T, Xiao Y, Cai H, Ding J. Human epididymis protein 4 is associated with severity and poor prognosis of connective tissue disease-associated interstitial lung disease with usual interstitial pneumonia pattern. International Immunopharmacology 2022;108:108704. [DOI: 10.1016/j.intimp.2022.108704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Liu GY, Budinger GRS, Dematte JE. Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. BMJ. [DOI: 10.1136/bmj-2021-066354] [Reference Citation Analysis]
14 Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, Terrioux P; OrphaLung. [French practical guidelines for the diagnosis and management of IPF - 2021 update, full version]. Rev Mal Respir 2022:S0761-8425(22)00035-3. [PMID: 35752506 DOI: 10.1016/j.rmr.2022.01.014] [Reference Citation Analysis]
15 Molina-molina M, Kreuter M, Cottin V, Corte TJ, Gilberg F, Kirchgaessler K, Axmann J, Maher TM. Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis. Front Med 2022;9:897102. [DOI: 10.3389/fmed.2022.897102] [Reference Citation Analysis]
16 Diesler R, Cottin V. Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies. Expert Rev Respir Med 2022. [PMID: 35695895 DOI: 10.1080/17476348.2022.2089116] [Reference Citation Analysis]
17 Shan L, Wang F, Zhai D, Meng X, Liu J, Lv X. New Drugs for Hepatic Fibrosis. Front Pharmacol 2022;13:874408. [DOI: 10.3389/fphar.2022.874408] [Reference Citation Analysis]
18 Zhou X, Yang D, Kong X, Wei C, Lvqiu S, Wang L, Lin Y, Yin Z, Zhou Z, Luo H. Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis. Front Med 2022;9:925703. [DOI: 10.3389/fmed.2022.925703] [Reference Citation Analysis]
19 Wells AU. Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management. Ann Am Thorac Soc 2022;19:904-6. [PMID: 35648081 DOI: 10.1513/AnnalsATS.202204-323ED] [Reference Citation Analysis]
20 Layoun H, Hajal J, Saliba Y, Smayra V, Habr B, Fares N. Pirfenidone mitigates TGF-β1-mediated fibrosis in an idiopathic inflammatory myositis-associated interstitial lung disease model. Cytokine 2022;154:155899. [DOI: 10.1016/j.cyto.2022.155899] [Reference Citation Analysis]
21 Miedema JR, Moor CC, Veltkamp M, Baart S, Lie NSL, Grutters JC, Wijsenbeek MS, Mostard RLM. Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study. Respir Res 2022;23. [DOI: 10.1186/s12931-022-02061-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wang J, Wang X, Qi X, Sun Z, Zhang T, Cui Y, Shu Q. The Efficacy and Safety of Pirfenidone Combined With Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study. Front Med 2022;9:871861. [DOI: 10.3389/fmed.2022.871861] [Reference Citation Analysis]
23 Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, Antoniou KM, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M, Wilson KC. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022;205:e18-47. [PMID: 35486072 DOI: 10.1164/rccm.202202-0399ST] [Cited by in Crossref: 57] [Cited by in F6Publishing: 24] [Article Influence: 57.0] [Reference Citation Analysis]
24 Marinescu DC, Churg A. Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases: The Glass Is Half Full. Ann Am Thorac Soc 2022;19:720-2. [PMID: 35486083 DOI: 10.1513/AnnalsATS.202111-1315ED] [Reference Citation Analysis]
25 Wong AW, Fisher JH. The Genomic Classifier and Our Quest for Diagnostic Certainty in Interstitial Lung Disease. Ann Am Thorac Soc 2022;19:725-7. [PMID: 35486084 DOI: 10.1513/AnnalsATS.202107-873ED] [Reference Citation Analysis]
26 Dolivo DM. Anti-fibrotic effects of pharmacologic FGF-2: a review of recent literature. J Mol Med (Berl) 2022. [PMID: 35484303 DOI: 10.1007/s00109-022-02194-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Wong AW, Koo J, Ryerson CJ, Sadatsafavi M, Chen W. A systematic review on the economic burden of interstitial lung disease and the cost-effectiveness of current therapies. BMC Pulm Med 2022;22:148. [PMID: 35443657 DOI: 10.1186/s12890-022-01922-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Aimo A, Spitaleri G, Nieri D, Tavanti LM, Meschi C, Panichella G, Lupón J, Pistelli F, Carrozzi L, Bayes-genis A, Emdin M. Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond. Card Fail Rev 2022;8:e12. [DOI: 10.15420/cfr.2021.30] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
29 Tanizawa K, Handa T, Nagai S, Ikezoe K, Kubo T, Yokomatsu T, Ueda S, Fushimi Y, Ogino S, Watanabe K, Nakatsuka Y, Hirai T, Izumi T. Lung function decline in sarcoidosis. Respir Investig 2022:S2212-5345(22)00026-0. [PMID: 35400618 DOI: 10.1016/j.resinv.2022.02.009] [Reference Citation Analysis]
30 Kinoshita Y, Miyamura T, Ikeda T, Ueda Y, Yoshida Y, Kushima H, Ishii H. Limited efficacy of nintedanib for idiopathic pleuroparenchymal fibroelastosis. Respir Investig 2022:S2212-5345(22)00025-9. [PMID: 35398003 DOI: 10.1016/j.resinv.2022.03.001] [Reference Citation Analysis]
31 Case AH. Clinical Overview of Progressive Fibrotic Interstitial Lung Disease. Front Med (Lausanne) 2022;9:858339. [PMID: 35372405 DOI: 10.3389/fmed.2022.858339] [Reference Citation Analysis]
32 Molina-molina M, Buendia-roldan I, Castillo D, Caro F, Valenzuela C, Selman M. [Translated article] Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis. Archivos de Bronconeumología 2022. [DOI: 10.1016/j.arbres.2021.12.017] [Reference Citation Analysis]
33 Kishaba T. Current perspective of progressive-fibrosing interstitial lung disease. Respiratory Investigation 2022. [DOI: 10.1016/j.resinv.2022.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Cottin V, Bonniaud P, Cadranel J, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Crestani B. [Idiopathic pulmonary fibrosis: Update of French practical guidelines]. Rev Mal Respir 2022:S0761-8425(22)00135-8. [PMID: 35337709 DOI: 10.1016/j.rmr.2022.03.004] [Reference Citation Analysis]
35 Prior TS, Hyldgaard C, Torrisi SE, Kronborg-White S, Ganter C, Bendstrup E, Kreuter M. Comorbidities in unclassifiable interstitial lung disease. Respir Res 2022;23:59. [PMID: 35296320 DOI: 10.1186/s12931-022-01981-3] [Reference Citation Analysis]
36 Takei R, Brown KK, Yamano Y, Kataoka K, Yokoyama T, Matsuda T, Kimura T, Suzuki A, Furukawa T, Fukuoka J, Johkoh T, Goto Y, Kondoh Y. Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype. Respirology 2022. [PMID: 35293077 DOI: 10.1111/resp.14245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, Terrioux P; OrphaLung. [French practical guidelines for the diagnosis and management of IPF - 2021 update, short version]. Rev Mal Respir 2022:S0761-8425(22)00026-2. [PMID: 35304014 DOI: 10.1016/j.rmr.2022.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
38 Swigris JJ, Bushnell DM, Rohr K, Mueller H, Baldwin M, Inoue Y. Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases. BMJ Open Resp Res 2022;9:e001167. [DOI: 10.1136/bmjresp-2021-001167] [Reference Citation Analysis]
39 Cottin V, Teague R, Nicholson L, Langham S, Baldwin M. The Burden of Progressive-Fibrosing Interstitial Lung Diseases. Front Med (Lausanne) 2022;9:799912. [PMID: 35178411 DOI: 10.3389/fmed.2022.799912] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
40 Liang M, Matteson EL, Abril A, Distler JH. The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease. Therapeutic Advances in Musculoskeletal 2022;14:1759720X2210744. [DOI: 10.1177/1759720x221074457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Xue M, Zhang T, Lin R, Zeng Y, Cheng ZJ, Li N, Zheng P, Huang H, Zhang XD, Wang H, Sun B. Clinical utility of heparin‐binding protein as an acute‐phase inflammatory marker in interstitial lung disease. J Leukocyte Bio. [DOI: 10.1002/jlb.3ma1221-489r] [Reference Citation Analysis]
42 Curran CS, Kopp JB. Aryl Hydrocarbon Receptor Mechanisms Affecting Chronic Kidney Disease. Front Pharmacol 2022;13:782199. [DOI: 10.3389/fphar.2022.782199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
43 Kreuter M, Maher TM, Corte TJ, Molina-Molina M, Axmann J, Gilberg F, Kirchgaessler KU, Cottin V. Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use. Adv Ther 2022;39:1081-95. [PMID: 34936057 DOI: 10.1007/s12325-021-02009-w] [Reference Citation Analysis]
44 Yu QY, Tang XX. Irreversibility of Pulmonary Fibrosis. Aging Dis 2022;13:73-86. [PMID: 35111363 DOI: 10.14336/AD.2021.0730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Rossi G, Spagnolo P, Wuyts WA, Ryerson CJ, Valli M, Valentini I, Grani G, Gennari A, Bizzarro T, Lazzari-agli L. Pathologic comparison of conventional video-assisted thoracic surgical (VATS) biopsy versus non-intubated/“awake” biopsy in fibrosing interstitial lung diseases. Respiratory Medicine 2022. [DOI: 10.1016/j.rmed.2022.106777] [Reference Citation Analysis]
46 Gan D, Cheng W, Ke L, Sun AR, Jia Q, Chen J, Xu Z, Xu J, Zhang P. Biphasic Effect of Pirfenidone on Angiogenesis. Front Pharmacol 2021;12:804327. [PMID: 35069215 DOI: 10.3389/fphar.2021.804327] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Popmihajlov Z, Sutherland DJ, Horan GS, Ghosh A, Lynch DA, Noble PW, Richeldi L, Reiss TF, Greenberg S. CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial. BMJ Open Resp Res 2022;9:e001060. [DOI: 10.1136/bmjresp-2021-001060] [Reference Citation Analysis]
48 Torrisi SE, Kahn N, Wälscher J, Polke M, Lee JS, Molyneaux PL, Sambataro FM, Heussel CP, Vancheri C, Kreuter M. Outcomes and Incidence of PF-ILD According to Different Definitions in a Real-World Setting. Front Pharmacol 2021;12:790204. [PMID: 34975486 DOI: 10.3389/fphar.2021.790204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Althobiani M, Alqahtani JS, Hurst JR, Russell AM, Porter J. Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians. BMJ Open Respir Res 2021;8:e001088. [PMID: 34969772 DOI: 10.1136/bmjresp-2021-001088] [Reference Citation Analysis]
50 Corte TJ, Lancaster L, Swigris JJ, Maher TM, Goldin JG, Palmer SM, Suda T, Ogura T, Minnich A, Zhan X, Tirucherai GS, Elpers B, Xiao H, Watanabe H, Smith RA, Charles ED, Fischer A. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res 2021;8:e001026. [PMID: 34969771 DOI: 10.1136/bmjresp-2021-001026] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
51 Molina-molina M, Buendia I, Castillo D, Caro F, Valenzuela C, Selman M. Novedades diagnósticas y terapéuticas en fibrosis pulmonar progresiva. Archivos de Bronconeumología 2022. [DOI: 10.1016/j.arbres.2021.12.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 van den Bosch L, Luppi F, Ferrara G, Mura M. Immunomodulatory treatment of interstitial lung disease. Ther Adv Respir Dis 2022;16:17534666221117002. [PMID: 35938712 DOI: 10.1177/17534666221117002] [Reference Citation Analysis]
53 Mackintosh JA, Wells AU, Cottin V, Nicholson AG, Renzoni EA. Interstitial pneumonia with autoimmune features: challenges and controversies. Eur Respir Rev 2021;30:210177. [PMID: 34937706 DOI: 10.1183/16000617.0177-2021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Miądlikowska E, Rzepka-Wrona P, Miłkowska-Dymanowska J, Białas AJ, Piotrowski WJ. Review: Serum Biomarkers of Lung Fibrosis in Interstitial Pneumonia with Autoimmune Features-What Do We Already Know? J Clin Med 2021;11:79. [PMID: 35011819 DOI: 10.3390/jcm11010079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Althobiani MA, Evans RA, Alqahtani JS, Aldhahir AM, Russell AM, Hurst JR, Porter JC. Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: a systematic review. ERJ Open Res 2021;7:00441-2021. [PMID: 34938799 DOI: 10.1183/23120541.00441-2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Li F, Wang G, Zhang W, Zhang C. Efficacy and safety of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis caused by novel coronavirus disease: A protocol for Bayesian network meta-analysis. Medicine (Baltimore) 2021;100:e28282. [PMID: 34941111 DOI: 10.1097/MD.0000000000028282] [Reference Citation Analysis]
57 Wilfong EM, Aggarwal R. Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease. Ther Adv Musculoskelet Dis 2021;13:1759720X211060907. [PMID: 34917177 DOI: 10.1177/1759720X211060907] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Comes A, Sgalla G, Perrotta A, Richeldi L. Advances with pharmacotherapy for the treatment of interstitial lung disease. Expert Opin Pharmacother 2021;:1-13. [PMID: 34907821 DOI: 10.1080/14656566.2021.2016697] [Reference Citation Analysis]
59 Gagliardi M, Berg DV, Heylen CE, Koenig S, Hoton D, Tamirou F, Pieters T, Ghaye B, Froidure A. Real-life prevalence of progressive fibrosing interstitial lung diseases. Sci Rep 2021;11:23988. [PMID: 34907290 DOI: 10.1038/s41598-021-03481-8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
60 Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med 2021;21:411. [PMID: 34895203 DOI: 10.1186/s12890-021-01783-1] [Reference Citation Analysis]
61 Li S, Yang Q, Chen F, Tian L, Huo J, Meng Y, Tang Q, Wang W. The antifibrotic effect of pheretima protein is mediated by the TGF-β1/Smad2/3 pathway and attenuates inflammation in bleomycin-induced idiopathic pulmonary fibrosis. J Ethnopharmacol 2021;286:114901. [PMID: 34890730 DOI: 10.1016/j.jep.2021.114901] [Reference Citation Analysis]
62 Mackintosh JA, Pietsch M, Lutzky V, Enever D, Bancroft S, Apte SH, Tan M, Yerkovich ST, Dickinson JL, Pickett HA, Selvadurai H, Grainge C, Goh NS, Hopkins P, Glaspole I, Reynolds PN, Wrobel J, Jaffe A, Corte TJ, Chambers DC. TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis. BMJ Open Respir Res 2021;8:e001127. [PMID: 34857525 DOI: 10.1136/bmjresp-2021-001127] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Zhang M, Gao L, Ye Y, Li X. Advances in glioma-associated oncogene (GLI) inhibitors for cancer therapy. Invest New Drugs 2021. [PMID: 34837604 DOI: 10.1007/s10637-021-01187-2] [Reference Citation Analysis]
64 Kronborg-White S, Madsen LB, Bendstrup E, Poletti V. PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis. J Clin Med 2021;10:5562. [PMID: 34884264 DOI: 10.3390/jcm10235562] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
65 Tsitoura E, Trachalaki A, Vasarmidi E, Mastrodemou S, Margaritopoulos GA, Kokosi M, Fanidis D, Galaris A, Aidinis V, Renzoni E, Tzanakis N, Wells AU, Antoniou KM. Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality. Front Immunol 2021;12:645548. [DOI: 10.3389/fimmu.2021.645548] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Copeland CR, Lancaster LH. Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD). Front Med (Lausanne) 2021;8:743977. [PMID: 34722582 DOI: 10.3389/fmed.2021.743977] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Aronson KI, Suzuki A. Health Related Quality of Life in Interstitial Lung Disease: Can We Use the Same Concepts Around the World? Front Med (Lausanne) 2021;8:745908. [PMID: 34692737 DOI: 10.3389/fmed.2021.745908] [Reference Citation Analysis]
68 Ntatsoulis K, Karampitsakos T, Tsitoura E, Stylianaki EA, Matralis AN, Tzouvelekis A, Antoniou K, Aidinis V. Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target. Front Immunol 2021;12:687397. [PMID: 34671341 DOI: 10.3389/fimmu.2021.687397] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
69 van Batenburg AA, van Oosterhout MFM, Knoppert SN, Kazemier KM, van der Vis JJ, Grutters JC, Goldschmeding R, van Moorsel CHM. The Extent of Inflammatory Cell Infiltrate and Fibrosis in Lungs of Telomere- and Surfactant-Related Familial Pulmonary Fibrosis. Front Med (Lausanne) 2021;8:736485. [PMID: 34631753 DOI: 10.3389/fmed.2021.736485] [Reference Citation Analysis]
70 Nasser M, Si-Mohamed S, Turquier S, Traclet J, Ahmad K, Philit F, Bonniaud P, Chalabreysse L, Thivolet-Béjui F, Cottin V. Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis. Orphanet J Rare Dis 2021;16:419. [PMID: 34627338 DOI: 10.1186/s13023-021-02043-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
71 Villeneuve T, Prévot G, Lintz F, Mourin G, Ferry G, Bousquet E, Perelroizen H, Boghanim T, Faviez G, Noël-Savina E, Collot S, Le Borgne A, Didier A. [Epidemiology of fibrosing interstitial lung diseases in the department of Haute Garonne]. Rev Mal Respir 2021:S0761-8425(21)00365-X. [PMID: 34629221 DOI: 10.1016/j.rmr.2021.07.004] [Reference Citation Analysis]
72 Morrow LE, Hilleman D, Malesker MA. Management of patients with fibrosing interstitial lung diseases. Am J Health Syst Pharm 2021:zxab375. [PMID: 34608488 DOI: 10.1093/ajhp/zxab375] [Reference Citation Analysis]
73 Jiménez-ruiz CA, Valido Morales A, Perez Chica G, Urrutia Landa I, Rodriguez Portal JA, Arnedillo Muñoz A, Cózar Bernal F, Peces-barba G, Diego Roza C, Solano Reina S, Rodriguez Suarez P, Garcia Rio F, Salas Llinas E, Garcia Clemente MM, Valencia Gallardo JM, Rodriguez Nieto MJ, Martin de Carpi T, Sánchez de Cos Escuin J, Estrada Trigueros G, Godoy Mayoral R, Barbeta Sánchez E, Fernández Villar A, Ros Lucas JA, Martinez Moragón E, Tomás López L. Aspectos claves de la Neumología y la Cirugía Torácica sometidos a debate en la era COVID-19. Open Respiratory Archives 2021;3:100123. [DOI: 10.1016/j.opresp.2021.100123] [Reference Citation Analysis]
74 Suzuki Y, Mori K, Aono Y, Kono M, Hasegawa H, Yokomura K, Naoi H, Hozumi H, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Nakamura H, Suda T. Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis. Sci Rep 2021;11:18579. [PMID: 34535738 DOI: 10.1038/s41598-021-98161-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Churg A. Hypersensitivity pneumonitis: new concepts and classifications. Mod Pathol 2021. [PMID: 34531525 DOI: 10.1038/s41379-021-00866-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
76 Albera C, Verri G, Sciarrone F, Sitia E, Mangiapia M, Solidoro P. Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective. Biomedicines 2021;9:1237. [PMID: 34572422 DOI: 10.3390/biomedicines9091237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
77 Hu H, Keat K. Myeloperoxidase and associated lung disease: Review of the latest developments. Int J Rheum Dis 2021;24:1460-6. [PMID: 34498802 DOI: 10.1111/1756-185X.14213] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
78 Giannoni P, Grosso M, Fugazza G, Nizzari M, Capra MC, Bianchi R, Fiocca R, Salvi S, Montecucco F, Bertolotto M, Fais F, Salio M, Barisione E, de Totero D. Establishment and Characterization of a Novel Fibroblastic Cell Line (SCI13D) Derived from the Broncho-Alveolar Lavage of a Patient with Fibrotic Hypersensitivity Pneumonitis. Biomedicines 2021;9:1193. [PMID: 34572381 DOI: 10.3390/biomedicines9091193] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Barbera T, Davila L, Patel NM. Management and support of patients with fibrosing interstitial lung diseases. Nurse Pract 2021;46:39-44. [PMID: 34138813 DOI: 10.1097/01.NPR.0000743332.64602.aa] [Reference Citation Analysis]
80 Nambiar AM, Walker CM, Sparks JA. Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians. Ther Adv Respir Dis 2021;15:17534666211039771. [PMID: 34477452 DOI: 10.1177/17534666211039771] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
81 Nakshbandi G, Moor CC, Johannson KA, Maher TM, Kreuter M, Wijsenbeek MS. Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era. ERJ Open Res 2021;7:00405-2021. [PMID: 34471631 DOI: 10.1183/23120541.00405-2021] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
82 Boutou AK, Asimakos A, Kortianou E, Vogiatzis I, Tzouvelekis A. Long COVID-19 Pulmonary Sequelae and Management Considerations. J Pers Med 2021;11:838. [PMID: 34575615 DOI: 10.3390/jpm11090838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Leard LE, Holm AM, Valapour M, Glanville AR, Attawar S, Aversa M, Campos SV, Christon LM, Cypel M, Dellgren G, Hartwig MG, Kapnadak SG, Kolaitis NA, Kotloff RM, Patterson CM, Shlobin OA, Smith PJ, Solé A, Solomon M, Weill D, Wijsenbeek MS, Willemse BWM, Arcasoy SM, Ramos KJ. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2021;40:1349-79. [PMID: 34419372 DOI: 10.1016/j.healun.2021.07.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
84 Samarelli AV, Tonelli R, Marchioni A, Bruzzi G, Gozzi F, Andrisani D, Castaniere I, Manicardi L, Moretti A, Tabbì L, Cerri S, Beghè B, Dominici M, Clini E. Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players. Int J Mol Sci 2021;22:8952. [PMID: 34445658 DOI: 10.3390/ijms22168952] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
85 Isshiki T, Koyama K, Homma S, Sakamoto S, Yamasaki A, Shimizu H, Miyoshi S, Nakamura Y, Kishi K. Association of rs3750920 polymorphism in TOLLIP with clinical characteristics of fibrosing interstitial lung diseases in Japanese. Sci Rep 2021;11:16250. [PMID: 34376770 DOI: 10.1038/s41598-021-95869-9] [Reference Citation Analysis]
86 Zhang Y, Jin, Kang X, Zhou R, Sun Y, Lian F, Tong X. Signaling Pathways Involved in Diabetic Renal Fibrosis. Front Cell Dev Biol 2021;9:696542. [PMID: 34327204 DOI: 10.3389/fcell.2021.696542] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
87 Chen T, Tsai APY, Hur SA, Wong AW, Sadatsafavi M, Fisher JH, Johannson KA, Assayag D, Morisset J, Shapera S, Khalil N, Fell CD, Manganas H, Cox G, To T, Gershon AS, Hambly N, Halayko AJ, Wilcox PG, Kolb M, Ryerson CJ. Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respir Res 2021;22:202. [PMID: 34238283 DOI: 10.1186/s12931-021-01790-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Noth I, Cottin V, Chaudhuri N, Corte TJ, Johannson KA, Wijsenbeek M, Jouneau S, Michael A, Quaresma M, Rohr KB, Russell AM, Stowasser S, Maher TM; INMARK trial investigators. Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. Eur Respir J 2021;58:2001518. [PMID: 33419890 DOI: 10.1183/13993003.01518-2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
89 Guerrera F, Costardi L, Rosboch GL, Lyberis P, Ceraolo E, Solidoro P, Filippini C, Verri G, Brazzi L, Albera C, Ruffini E. Awake or intubated surgery in diagnosis of interstitial lung diseases? A prospective study. ERJ Open Res 2021;7:00630-2020. [PMID: 34235209 DOI: 10.1183/23120541.00630-2020] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
90 Wijsenbeek MS, Bendstrup E, Valenzuela C, Henry MT, Moor CC, Jouneau S, Fois AG, Moran-Mendoza O, Anees S, Mirt M, Bengus M, Gilberg F, Kirchgaessler KU, Vancheri C. Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study. Adv Ther 2021;38:4040-56. [PMID: 34117601 DOI: 10.1007/s12325-021-01790-y] [Reference Citation Analysis]
91 Trachalaki A, Tsitoura E, Mastrodimou S, Invernizzi R, Vasarmidi E, Bibaki E, Tzanakis N, Molyneaux PL, Maher TM, Antoniou K. Enhanced IL-1β Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis. Front Immunol 2021;12:661811. [PMID: 34220810 DOI: 10.3389/fimmu.2021.661811] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
92 Durheim MT, Hoffmann-Vold AM, Eagan TM, Hovden AO, Lund MB, Bjerke G, Birring SS, Jonassen TM, Johansen OE, Sjåheim T. ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF. BMJ Open Respir Res 2020;7:e000598. [PMID: 32576559 DOI: 10.1136/bmjresp-2020-000598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
93 Li Y, Zhu W, He H, Garov YA, Bai L, Zhang L, Wang J, Wang J, Zhou X. Efficacy and Safety of Tripterygium Wilfordii Hook. F for Connective Tissue Disease-Associated Interstitial Lung Disease:A Systematic Review and Meta-Analysis. Front Pharmacol 2021;12:691031. [PMID: 34177599 DOI: 10.3389/fphar.2021.691031] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
94 Shao T, Shi X, Yang S, Zhang W, Li X, Shu J, Alqalyoobi S, Zeki AA, Leung PS, Shuai Z. Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations. Front Immunol 2021;12:684699. [PMID: 34163483 DOI: 10.3389/fimmu.2021.684699] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
95 Funke-Chambour M, Bridevaux PO, Clarenbach CF, Soccal PM, Nicod LP, von Garnier C; Swiss COVID Lung Study Group and the Swiss Society of Pulmonology. Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID. Respiration 2021;100:826-41. [PMID: 34091456 DOI: 10.1159/000517255] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
96 Rurik JG, Aghajanian H, Epstein JA. Immune Cells and Immunotherapy for Cardiac Injury and Repair. Circ Res 2021;128:1766-79. [PMID: 34043424 DOI: 10.1161/CIRCRESAHA.121.318005] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
97 Shumar JN, Chandel A, King CS. Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD. J Clin Med 2021;10:2285. [PMID: 34070297 DOI: 10.3390/jcm10112285] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
98 Nasser M, Larrieu S, Boussel L, Si-Mohamed S, Bazin F, Marque S, Massol J, Thivolet-Bejui F, Chalabreysse L, Maucort-Boulch D, Hachulla E, Jouneau S, Le Lay K, Cottin V. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study). Respir Res 2021;22:162. [PMID: 34030695 DOI: 10.1186/s12931-021-01749-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
99 Moor CC, van Leuven SI, Wijsenbeek MS, Vonk MC. Feasibility of online home spirometry in systemic sclerosis-associated interstitial lung disease: a pilot study. Rheumatology (Oxford) 2021;60:2467-71. [PMID: 33212511 DOI: 10.1093/rheumatology/keaa607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
100 Bowman WS, Echt GA, Oldham JM. Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response. Front Med (Lausanne) 2021;8:680997. [PMID: 34041256 DOI: 10.3389/fmed.2021.680997] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
101 Yamagata A, Arita M, Tachibana H, Tokioka F, Sugimoto C, Sumikawa H, Tanaka T, Yasui H, Fujisawa T, Nakamura Y, Suda T, Ishida T. Impact of bronchoalveolar lavage lymphocytosis on the effects of anti-inflammatory therapy in idiopathic non-specific interstitial pneumonia, idiopathic pleuroparenchymal fibroelastosis, and unclassifiable idiopathic interstitial pneumonia. Respir Res 2021;22:115. [PMID: 33879137 DOI: 10.1186/s12931-021-01726-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Choi W. Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions. Precis Future Med 2021;5:31-40. [DOI: 10.23838/pfm.2020.00205] [Reference Citation Analysis]
103 Lang D, Akbari K, Horner A, Hepp M, Kaiser B, Pieringer H, Lamprecht B. Computed Tomography Findings as Determinants of Local and Systemic Inflammation Biomarkers in Interstitial Lung Diseases: A Retrospective Registry-Based Descriptive Study. Lung 2021;199:155-64. [PMID: 33770227 DOI: 10.1007/s00408-021-00434-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Khor YH, Saravanan K, Holland AE, Lee JYT, Ryerson CJ, McDonald CF, Goh NSL. A mixed-methods pilot study of handheld fan for breathlessness in interstitial lung disease. Sci Rep 2021;11:6874. [PMID: 33767311 DOI: 10.1038/s41598-021-86326-8] [Reference Citation Analysis]
105 Goos T, De Sadeleer LJ, Yserbyt J, Verleden GM, Vermant M, Verleden SE, Wuyts WA. Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be. J Clin Med 2021;10:1330. [PMID: 33807034 DOI: 10.3390/jcm10061330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
106 Lu ZH, Yang CL, Yang GG, Pan WX, Tian LG, Zheng JX, Lv S, Zhang SY, Zheng PY, Zhang SX. Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial. Infect Dis Poverty 2021;10:31. [PMID: 33731163 DOI: 10.1186/s40249-021-00813-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
107 Kang EH, Song YW. Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases. Pharmaceuticals (Basel) 2021;14:251. [PMID: 33802193 DOI: 10.3390/ph14030251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
108 Adegunsoye A, Morisset J, Newton CA, Oldham JM, Vittinghoff E, Linderholm AL, Strek ME, Noth I, Garcia CK, Wolters PJ, Ley B. Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis. Eur Respir J 2021;57:2002872. [PMID: 33122338 DOI: 10.1183/13993003.02872-2020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
109 Katano T, Sekine A, Ikeda S, Yamakawa H, Misumi T, Okabayashi H, Okuda R, Kitamura H, Baba T, Komatsu S, Hagiwara E, Ogura T. Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease. Respir Investig 2021;59:414-20. [PMID: 33618993 DOI: 10.1016/j.resinv.2021.01.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Fernandes AL, Ferreira J, Neves I. Interstitial pneumonia with autoimmune features: A case series and overview. Respir Med Case Rep 2021;32:101350. [PMID: 33552894 DOI: 10.1016/j.rmcr.2021.101350] [Reference Citation Analysis]
111 Markart P, Drakopanagiotakis F, Wygrecka M. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases]. Dtsch Med Wochenschr 2021;146:181-4. [PMID: 33513653 DOI: 10.1055/a-1239-3728] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Goodwin AT, Saini G. Supportive care of patients with fibrosing interstitial lung disease: answering a great clinical need. Breathe (Sheff) 2020;16:200066. [PMID: 33447270 DOI: 10.1183/20734735.0066-2020] [Reference Citation Analysis]
113 Cassone G, Sebastiani M, Vacchi C, Erre GL, Salvarani C, Manfredi A. Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review. Drugs Context 2021;10:2020-8-8. [PMID: 33505480 DOI: 10.7573/dic.2020-8-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Erre GL, Sebastiani M, Manfredi A, Gerratana E, Atzeni F, Passiu G, Mangoni AA. Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications. Drugs Context 2021;10:2020-8-6. [PMID: 33505482 DOI: 10.7573/dic.2020-8-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
115 Sgalla G, Mari PV, Richeldi L. Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't. Ann Transl Med 2020;8:1615. [PMID: 33437814 DOI: 10.21037/atm-20-3243] [Reference Citation Analysis]
116 Sebastiani M, Faverio P, Manfredi A, Cassone G, Vacchi C, Stainer A, Pozzi MR, Salvarani C, Pesci A, Luppi F. Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential. Biomedicines 2020;9:17. [PMID: 33375368 DOI: 10.3390/biomedicines9010017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
117 Pullamsetti SS, Günther A. A FOX-like Mechanism Regulating Lung Fibroblasts: Are We Getting There? Am J Respir Cell Mol Biol 2020;63:723-4. [PMID: 33091319 DOI: 10.1165/rcmb.2020-0441ED] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
118 Durheim MT. Toward Realizing the Full Potential of Registries in Interstitial Lung Disease. Ann Am Thorac Soc 2020;17:1534-5. [PMID: 33258673 DOI: 10.1513/AnnalsATS.202008-1077ED] [Reference Citation Analysis]
119 Jee AS, Sheehy R, Hopkins P, Corte TJ, Grainge C, Troy LK, Symons K, Spencer LM, Reynolds PN, Chapman S, de Boer S, Reddy T, Holland AE, Chambers DC, Glaspole IN, Jo HE, Bleasel JF, Wrobel JP, Dowman L, Parker MJS, Wilsher ML, Goh NSL, Moodley Y, Keir GJ. Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand. Respirology 2021;26:23-51. [PMID: 33233015 DOI: 10.1111/resp.13977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
120 Verleden SE, Braubach P, Kuehnel M, Dickgreber N, Brouwer E, Tittmann P, Laenger F, Jonigk D. Molecular approach to the classification of chronic fibrosing lung disease-there and back again. Virchows Arch 2021;478:89-99. [PMID: 33169196 DOI: 10.1007/s00428-020-02964-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
121 Nathan SD, Pastre J, Ksovreli I, Barnett S, King C, Aryal S, Ahmad K, Fukuda C, Ramalingam V, Chung JH. HRCT evaluation of patients with interstitial lung disease: comparison of the 2018 and 2011 diagnostic guidelines. Ther Adv Respir Dis 2020;14:1753466620968496. [PMID: 33121391 DOI: 10.1177/1753466620968496] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
122 Johannson KA. Remote Monitoring in Idiopathic Pulmonary Fibrosis: Home Is Where the Bluetooth-enabled Spirometer Is. Am J Respir Crit Care Med 2020;202:316-7. [PMID: 32402209 DOI: 10.1164/rccm.202005-1532ED] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
123 Dhooria S, Agarwal R, Sehgal IS, Prasad KT, Muth V, Garg M, Bal A, Aggarwal AN, Behera D. A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2020;37:148-57. [PMID: 33093778 DOI: 10.36141/svdld.v37i2.8718] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
124 Veit T, Barnikel M, Crispin A, Kneidinger N, Ceelen F, Arnold P, Munker D, Schmitzer M, Barton J, Schiopu S, Schiller HB, Frankenberger M, Milger K, Behr J, Neurohr C, Leuschner G. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study. Respir Res 2020;21:270. [PMID: 33076914 DOI: 10.1186/s12931-020-01524-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
125 Feng H, Zhao Y, Li Z, Kang J. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients. Ther Adv Respir Dis 2020;14:1753466620963015. [PMID: 33070705 DOI: 10.1177/1753466620963015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
126 Nakshbandi G, Moor CC, Wijsenbeek MS. Home monitoring for patients with ILD and the COVID-19 pandemic. Lancet Respir Med 2020;8:1172-4. [PMID: 33075296 DOI: 10.1016/S2213-2600(20)30452-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
127 Spagnolo P, Distler O, Ryerson CJ, Tzouvelekis A, Lee JS, Bonella F, Bouros D, Hoffmann-Vold AM, Crestani B, Matteson EL. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis 2021;80:143-50. [PMID: 33037004 DOI: 10.1136/annrheumdis-2020-217230] [Cited by in Crossref: 14] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
128 Cruwys S, Hein P, Humphries B, Black D. Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities. Drug Discov Today 2020;25:2277-83. [PMID: 33010480 DOI: 10.1016/j.drudis.2020.09.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
129 Yang J, Hu H, Zhang S, Jiang L, Cheng Y, Xie H, Wang X, Jiang J, Wang H, Zhang Q. [Human umbilical cord mesenchymal stem cell-derived exosomes alleviate pulmonary fibrosis in mice by inhibiting epithelial-mesenchymal transition]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:988-94. [PMID: 32895166 DOI: 10.12122/j.issn.1673-4254.2020.07.11] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
130 Huang S, Kronzer VL, Dellaripa PF, Deane KD, Bolster MB, Nagaraja V, Khanna D, Doyle TJ, Sparks JA. Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment. Curr Treatm Opt Rheumatol 2020;6:337-53. [PMID: 33282632 DOI: 10.1007/s40674-020-00160-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
131 Vitiello A, Pelliccia C, Ferrara F. COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy.SN Compr Clin Med. 2020;1-4. [PMID: 32875276 DOI: 10.1007/s42399-020-00487-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
132 Costabel U, Miyazaki Y, Pardo A, Koschel D, Bonella F, Spagnolo P, Guzman J, Ryerson CJ, Selman M. Hypersensitivity pneumonitis. Nat Rev Dis Primers 2020;6:65. [PMID: 32764620 DOI: 10.1038/s41572-020-0191-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
133 Wuyts WA, Papiris S, Manali E, Kilpeläinen M, Davidsen JR, Miedema J, Robalo-Cordeiro C, Morais A, Artés M, Asijee G, Cendoya D, Soulard S. The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach. Adv Ther 2020;37:3246-64. [PMID: 32445186 DOI: 10.1007/s12325-020-01384-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
134 Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection? Eur J Clin Pharmacol 2020;76:1615-8. [PMID: 32594204 DOI: 10.1007/s00228-020-02947-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 37] [Article Influence: 12.5] [Reference Citation Analysis]
135 Sarkar P, Avram C, Chaudhuri N. The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease. Expert Rev Respir Med 2020;14:1001-8. [PMID: 32567402 DOI: 10.1080/17476348.2020.1784730] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 De Sadeleer LJ, Goos T, Yserbyt J, Wuyts WA. Towards the Essence of Progressiveness: Bringing Progressive Fibrosing Interstitial Lung Disease (PF-ILD) to the Next Stage. J Clin Med 2020;9:E1722. [PMID: 32503224 DOI: 10.3390/jcm9061722] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
137 Adegunsoye A, Alqalyoobi S, Linderholm A, Bowman WS, Lee CT, Pugashetti JV, Sarma N, Ma SF, Haczku A, Sperling A, Strek ME, Noth I, Oldham JM. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest 2020;158:1526-34. [PMID: 32450241 DOI: 10.1016/j.chest.2020.04.066] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
138 George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med 2020;8:807-15. [PMID: 32422178 DOI: 10.1016/S2213-2600(20)30225-3] [Cited by in Crossref: 279] [Cited by in F6Publishing: 443] [Article Influence: 139.5] [Reference Citation Analysis]
139 Azuma A, Richeldi L. New Era of Management Concept on Pulmonary Fibrosis with Revisiting Framework of Interstitial Lung Diseases. Tuberc Respir Dis (Seoul) 2020;83:195-200. [PMID: 32578412 DOI: 10.4046/trd.2020.0005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
140 Wong AW, Fidler L, Marcoux V, Johannson KA, Assayag D, Fisher JH, Hambly N, Kolb M, Morisset J, Shapera S, Ryerson CJ. Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. Chest 2020;158:1069-78. [PMID: 32333929 DOI: 10.1016/j.chest.2020.04.019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 39] [Article Influence: 14.0] [Reference Citation Analysis]
141 Kropski JA. Familial Interstitial Lung Disease. Semin Respir Crit Care Med 2020;41:229-37. [PMID: 32279293 DOI: 10.1055/s-0040-1708054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
142 Moor CC, van den Berg CAL, Visser LS, Aerts JGJV, Cottin V, Wijsenbeek MS. Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry. ERJ Open Res 2020;6:00054-2020. [PMID: 32280666 DOI: 10.1183/23120541.00054-2020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
143 Cassone G, Sebastiani M, Vacchi C, Cerri S, Salvarani C, Manfredi A. Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming? Respir Med Case Rep 2020;30:101051. [PMID: 32292694 DOI: 10.1016/j.rmcr.2020.101051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
144 Vacchi C, Sebastiani M, Cassone G, Cerri S, Della Casa G, Salvarani C, Manfredi A. Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review. J Clin Med 2020;9:E407. [PMID: 32028635 DOI: 10.3390/jcm9020407] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
145 Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. Respir Res 2020;21:32. [PMID: 31996266 DOI: 10.1186/s12931-020-1296-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 13.5] [Reference Citation Analysis]
146 Tzouvelekis A, Bouros D. Endotyping of progressive fibrotic interstitial lung diseases: It is the final destination that matters and not the journey. EBioMedicine 2020;51:102591. [PMID: 31901856 DOI: 10.1016/j.ebiom.2019.11.052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]